Generic Obredon Availability
Last updated on Sep 10, 2025.
Obredon is a brand name of guaifenesin/hydrocodone, approved by the FDA in the following formulation(s):
OBREDON (guaifenesin; hydrocodone bitartrate - solution;oral)
-
Manufacturer: SOVEREIGN PHARMS
Approval date: November 14, 2014
Strength(s): 200MG/5ML;2.5MG/5ML (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Obredon. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Immediate release oral guaifenesin solution
Patent 10,105,324
Issued: October 23, 2018
Inventor(s): Hafey Paul
Assignee(s): SOVEREIGN PHARMACEUTICALS, LLCDisclosed is a method of treating or ameliorating a condition which can be treated or ameliorated by the administration of guaifenesin, which method comprises orally administering to a subject in need thereof an effective amount of an immediate release solution for oral administration of guaifenesin and at least one additional drug. In addition to water the solution comprises as solvents propylene glycol and glycerol in a concentration which significantly increases the bioavailability of guaifenesin in the human body.
Patent expiration dates:
- November 13, 2035✓✓✓
- November 13, 2035
-
Immediate release oral guaifenesin solution
Patent 9,549,907
Issued: January 24, 2017
Inventor(s): Hafey Paul
Assignee(s): SOVEREIGN PHARMACEUTICALS, LLCDisclosed is an immediate release solution for oral administration of guaifenesin and at least one additional drug. In addition to water the solution comprises as solvents propylene glycol and glycerol in a concentration which significantly increases the bioavailability of guaifenesin in the human body.
Patent expiration dates:
- November 13, 2035✓✓✓
- November 13, 2035
-
Immediate release oral guaifenesin solution
Patent 9,808,431
Issued: November 7, 2017
Inventor(s): Hafey Paul
Assignee(s): Sovereign Pharmaceuticals, LLCDisclosed is an immediate release solution for oral administration of guaifenesin and at least one additional drug. In addition to water the solution comprises as solvents propylene glycol and glycerol in a concentration which significantly increases the bioavailability of guaifenesin in the human body.
Patent expiration dates:
- November 13, 2035✓✓✓
- November 13, 2035
More about Obredon (guaifenesin / hydrocodone)
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: upper respiratory combinations
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.